BETHESDA, Md., Dec. 6, 2013 /PRNewswire/ -- TRI's Data Management and Biostatistics staff contributed to a study on the response to cancer therapy of an intact population of microorganisms living in the intestine. The study was a collaborative effort with scientists at the National Cancer Institute. Led by Romina Goldszmid, Ph.D. and Giorgio Trinchieri, M.D., both at NCI, it was published Nov. 22, 2013, in Science.
The study found that tumors of germ-free mice (mice completely lacking these microorganisms), or mice treated with antibiotics to deplete the gut of bacteria, were largely impaired in their ability to respond to immunotherapy that slows cancer growth and prolongs survival. The mice were also impaired in their ability to respond to mainstay chemotherapy drugs such as oxaliplatin and cisplatin. These findings in mice may underscore the importance of microorganisms in optimal cancer treatment outcomes in humans.
TRI's contribution to this ground-breaking study included the statistical analysis of the effect of the presence or absence of the gut bacteria on the efficacy of different anti-cancer therapies, and of the underlying mechanisms.
About Technical Resources International, Inc. (TRI): TRI is a full-service contract research organization. TRI provides data management and statistical analysis services for all phases of clinical research as well as for toxicology and research program management. TRI's statisticians excel at determining the most suitable experimental designs and analytic approaches that focus on the outcomes and endpoints essential to the sponsor's objectives. For over 34 years, TRI has provided support to government agencies, the private sector, and non-profit organizations. Further information is available at www.tech-res.com.
SOURCE Technical Resources International, Inc.